• Written informed consent obtained.

• Age ≥ 18 years at time of study entry.

• Participants must have gastric cancer liver metastasis.

• Participants must have failed at least one previous systemic chemotherapy regimens in the liver metastatic setting.

• Participants who had received previous anti-angiogenesis or anti-PD1/PDL1 therapy were eligible.

• At least one measurable site of disease as defined by RECIST v1.1 with spiral CT scan or MRI.

• Performance status (PS) ≤ 2 (ECOG scale).

• Life expectancy of at least 12 weeks.

• Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1,500/L, platelets ≥75 x103/L; Total bilirubin ≤ 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31 g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula )

• Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.

• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits and examinations including follow up.